Cepheid receives FDA emergency use authorization for SARS-CoV-2 test
The Xpert Xpress SARS-CoV-2 test is designed for the qualitative detection of the virus causing COVID-19
The Xpert Xpress SARS-CoV-2 test is designed for the qualitative detection of the virus causing COVID-19
The collaboration aims to develop novel, targeted treatments to address significant unmet needs
Scientists say early data, generated with new NGS research panel from Thermo Fisher Scientific, suggest coronavirus is genetically stable, and could increase the effectiveness of vaccines in development
Sartorius supports the development of the first vaccine candidate against the novel coronavirus to enter clinical trials
AI-driven proteogenomic analysis company applies single-cell analysis expertise to develop treatments for COVID-19
Roche Group has provided an update on the various actions the company is taking to address the COVID-19 pandemic
The test will be used on the m2000 RealTime system that is currently available in hospitals and molecular laboratories in the U.S.
The company seeks quick clearance of the test through an FDA emergency use authorization
Chairman and CEO Albert Bourla calls on biopharma industry to collaborate on combating the global pandemic
The Standard is said to contain synthetic COVID-19 RNA transcripts and human genomic DNA
Seeking a shortcut to treatment for the novel coronavirus pandemic, Sanofi and Regeneron will roll out phase 2/3 trials of the arthritis drug
The test kit aims to differentiate novel coronavirus from 21 other pathogens implicated in respiratory syndromes
IDT's primer and probe kit can be used as a component of the CDC testing protocol for the diagnosis and detection of COVID-19
The FDA has issued its fourth Emergency Use Authorization for coronavirus tests, this time to Thermo Fisher Scientific for its TaqPath COVID-19 Combo Kit
The first commercial test for SARS-CoV-2 will enable expedited coronavirus testing to meet urgent medical needs
Logix Smart™ COVID-19 test CE marked & available in Europe four weeks after project initiation
Positive in vivo efficacy and pharmacokinetic data shows AVA04-VbP drug conjugate out-performed Bavencio immunotherapy
The molecule points the way toward treating viruses that cross from animals to humans
The antibody is being trialed for use in the treatment of B cell Acute Lymphoblastic Leukemia